Functional outcomes after treatment of advanced oropharyngeal carcinoma with radiation or chemoradiation

Journal of Otolaryngology - Head and Neck Surgery

Volumn 41, Issue 2, 2012, Pages 108-118

  Myers, Candace ^a   Kerr, Paul ^b   Cooke, Andrew ^a   Bammeke, Femi ^b   Butler, James ^a   Lambert, Pascal ^a  

^a CANCERCARE MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Carcinoma; Oropharyngeal; Outcomes

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; TIRAPAZAMINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; OROPHARYNX SQUAMOUS CELL CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALATE DISEASE; PERFORMANCE STATUS SCALE FOR HEAD AND NECK CANCER PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; ROYAL BRISBANE HOSPITAL SWALLOWING SCALE; SOFT PALATE; SOFT PALATE CARCINOMA; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TONSIL CARCINOMA; TREATMENT OUTCOME; VOICE HANDICAP INDEX 10;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DEGLUTITION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; OROPHARYNX; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862581205     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2011.110211     Document Type: Article

References (41)

1. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28, doi:10.1186/1471-2407-6-28.
2. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55. (Pubitemid 30148259)
3. Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004;26:796-807, doi:10.1002/hed.20045. (Pubitemid 39159303)
4. Munter MW, Hoffner S, Hof H, et al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. Int J Radiat Oncol Biol Phys 2007;67:651-9, doi:10.1016/j.ijrobp.2006.09.035. (Pubitemid 46215873)
5. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007;68:1289-98, doi:10.1016/j.ijrobp.2007.02.049. (Pubitemid 47176817)
6. Kotz T, Costello R, Li Y, Posner MR. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck 2004;26:365-72, doi:10.1002/hed.10385. (Pubitemid 38436676)
7. Rancati T, Fiorino C, Sanguineti G. NTCP modeling of subacute/late laryngeal edema scored by fiberoptic examination. Int J Radiat Oncol Biol Phys 2009;75:915-23, doi:10.1016/j.ijrobp.2009.04.087.
8. Tschiesner U, Rogers S, Dietz A, et al. Development of ICF core sets for head and neck cancer. Head Neck 2010;32:210-20.
9. List MA, Mumby P, Haraf D, et al. Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. Qual Life Res 1997;6:274-84, doi:10.1023/A:1026419023481. (Pubitemid 27293874)
10. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol 1999;17:1020-8. (Pubitemid 29109336)
11. Tobias JS, Monson K, Gupta N, et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol 2010;11:66-74, doi:10.1016/S1470-2045(09)70306-7.
12. Fang FM, Tsai WL, Chien CY, et al. Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation. Oncology 2005;68:405-13, doi:10.1159/000086982.
13. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:23-8, doi:10.1016/S0360-3016(02)02712-8. (Pubitemid 34465803)
14. Hassanein KA, Musgrove BT, Bradbury E. Psychological outcome of patients following treatment of oral cancer and its relation with functional status and coping mechanisms. J Craniomaxillofac Surg 2005;33:404-9, doi:10.1016/j.jcms. 2005.05.005. (Pubitemid 41644445)
15. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:401-8, doi:10.1001/archotol.130.4.401. (Pubitemid 38456313)
16. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66:981-91, doi:10.1016/j.ijrobp.2006.06.013. (Pubitemid 44633504)
17. Murthy V, Gupta T, Kadam A, et al. Time trial: a prospective comparative study of the time-resource burden for three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in head and neck cancers. J Cancer Res Ther 2009;5:107-12, doi:10.4103/0973-1482.52800.
18. Clark CH, Hansen VN, Chantler H, et al. Dosimetry audit for a multi-centre IMRT head and neck trial. Radiother Oncol 2009;93:102-8, doi:10.1016/j.radonc.2009.04.025.
19. Veldeman L, Madani I, Hulstaert F, et al. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008;9:367-75, doi:10.1016/S1470-2045(08)70098-6. (Pubitemid 351411653)
20. Clark CH, Miles EA, Urbano MT, et al. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. Br J Radiol 2009;82:585-94, doi:10.1259/bjr/31966505.
21. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:4873-9, doi:10.1200/JCO.2007.11.5501. (Pubitemid 350220416)
22. Eadie TL. The ICF: a proposed framework for comprehensive rehabilitation of individuals who use alaryngeal speech. Am J Speech Lang Pathol 2003;12:189-97, doi:10.1044/1058-0360(2003/065). (Pubitemid 36707080)
23. Tschiesner U, Cieza A, Rogers SN, et al. Developing core sets for patients with head and neck cancer based on the International Classification of Functioning, Disability and Health (ICF). Eur Arch Otorhinolaryngol 2007;264:1215-22, doi:10.1007/s00405-007-0335-8. (Pubitemid 350194838)
24. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984;53:2002-7, doi:10.1002/1097-0142(19840501)53:9〈2002:: AID-CNCR2820530933〉3.0.CO;2-W. (Pubitemid 14127662)
25. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55, doi:10.1097/00000421-198212000-00014. (Pubitemid 13149996)
26. List MA, Ritter-Sterr C, Lansky SB. A performance status scale for head and neck cancer patients. Cancer 1990;66:564-9, doi:10.1002/1097-0142(19900801) 66:3〈564::AID-CNCR2820660326〉3.0.CO;2-D. (Pubitemid 20233457)
27. List MA, D'Antonio LL, Cella DF, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer 1996;77:2294-301, doi:10.1002/(SICI)1097-0142(19960601)77:11〈2294::AID- CNCR17〉3.0.CO;2-S. (Pubitemid 26162422)
28. Ward E, Conroy A. Validity, reliability and responsiveness of the Royal Brisbane Hospital Outcome Measure for swallowing. Asia Pac J Speech Lang Hear 1999;4:109-29.
29. Rosen CA, Lee AS, Osborne J, et al. Development and validation of the Voice Handicap Index-10. Laryngoscope 2004;114:1549-56, doi:10.1097/00005537- 200409000-00009. (Pubitemid 39278869)
30. Curran D, Bacchi M, Schmitz SF, et al. Identifying the types of missingness in quality of life data from clinical trials. Stat Med 1998;17:739-56, doi:10.1002/(SICI)1097-0258(19980315/15)17:5/7〈739::AID- SIM818〉3.0.CO;2-M. (Pubitemid 28118943)
31. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring. Stat J 2007;4:445-64.
32. Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci 2007;8:206-13, doi:10.1007/s11121-007-0070-9.
33. Dijkema T, Terhaard CH, Roesink JM, et al. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:1101-9, doi:10.1016/j.ijrobp.2008.02.059.
34. Scrimger R, Kanji A, Parliament M, et al. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy. Am J Clin Oncol 2007;30:271-7, doi:10.1097/01.coc.0000258081.70643.3d. (Pubitemid 46884147)
35. Schwartz DL, Hutcheson K, Barringer D, et al. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:1356-65.
36. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 2010;28:2732-8, doi:10.1200/JCO.2009.24.6199.
37. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76, doi:10.1200/JCO.2004.08.021. (Pubitemid 41095116)
38. Olmi P, Crispino S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy - a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003;55:78-92, doi:10.1016/S0360-3016(02)03792-6. (Pubitemid 36020346)
39. Rieger J, Bohle G, Huryn J, et al. Surgical reconstruction versus prosthetic obturation of extensive soft palate defects: a comparison of speech outcomes. Int J Prosthodont 2009;22:566-72.
40. Seikaly H, Rieger J, Zalmanowitz J, et al. Functional soft palate reconstruction: a functional approach. Head Neck 2008;30:1615-23, doi:10.1002/hed.20919.
41. O'Connell DA, Rieger J, Harris JR, et al. Swallowing function in patients with base of tongue cancers treated with primary surgery and reconstructed with a modified radial forearm flap. Arch Otolaryngol Head Neck Surg 2008;134:857-64, doi:10.1001/archotol.134.8.857.